GGrantIndex
← Search

TRANSGENIC SHARED RESOURCE

$261,158P30FY2009CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

The transgenic shared resource was founded in 1988 to train and assist AECC investigators in the production and characterization of transgenic mouse strains. This technology allows analysis of gene function through the introduction of DMA sequences into the germ line, usually, although not exclusively, by pronuclear injection of fertilized oocytes. The shared resource supervisor director consults with individual investigators and advises on transgene construct, as well as making plasmids and sequence cassettes available, as well as other reagents. This results in DMA constructs suitable for expression in the mouse. Usually this is in the form of a plasmid but we also offer the injection of BAG DMA. The shared resource prepares the DNA and introduces this DNA into the oocytes by micro-injection. In some cases the sequence of interest is introduced into the oocyte by lentivirus infection. After the manipulation of the oocyte they are transferred to pseudo-pregnant mothers and following birth, the pups are cared for to weaning. At this point mice are returned to the investigator for further analysis. The production of useful transgenics usually takes less than seven weeks from submission of the DNA. We guarantee at least three founders per construct although generally more are generated. We have had essentially 100% success rate with little need for reinjection of constructs, Between 18-25 investigators use this service per year with approximately 100 constructs injected. In addition, the core provides embryo and sperm freezing for long-term storage of mouse lines, in vitro fertilization (IVF) and intra-cytoplasmic sperm injections (ICSI) to rescue frozen samples or difficult to mate strains. We also provide blastomere fusion to generate tetraploid embryos for aggregation with ES cells to determine whether the phenotypes of mutations are intrinsic to the embryo or are the result of placenta! abnormalities.

View original record on NIH RePORTER →